Ronan Lordan Ph.D., MA

Royal College of Surgeons in Ireland

Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use


Journal article


Kayla Barekat, Soumita Ghosh, Christin Herrmann, K. Keat, C. Assenmacher, Ceylan Tanes, Naomi G. Wilson, R. Lordan, Antonijo Mrcela, L. Rauova, Arjun Sengupta, U. S. Das, Robin Joshi, E. Friedman, M. Ritchie, K. Bittinger, A. Weljie, Ken Cadwell, Frederic D. Bushman, Gary D. Wu, G. Fitzgerald, E. Ricciotti
Journal of Clinical Investigation, 2026

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Barekat, K., Ghosh, S., Herrmann, C., Keat, K., Assenmacher, C., Tanes, C., … Ricciotti, E. (2026). Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use. Journal of Clinical Investigation.


Chicago/Turabian   Click to copy
Barekat, Kayla, Soumita Ghosh, Christin Herrmann, K. Keat, C. Assenmacher, Ceylan Tanes, Naomi G. Wilson, et al. “Concomitant COX-1 and COX-2 Suppression Is Not Sufficient to Induce Enteropathy Associated with Chronic NSAID Use.” Journal of Clinical Investigation (2026).


MLA   Click to copy
Barekat, Kayla, et al. “Concomitant COX-1 and COX-2 Suppression Is Not Sufficient to Induce Enteropathy Associated with Chronic NSAID Use.” Journal of Clinical Investigation, 2026.


BibTeX   Click to copy

@article{kayla2026a,
  title = {Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use},
  year = {2026},
  journal = {Journal of Clinical Investigation},
  author = {Barekat, Kayla and Ghosh, Soumita and Herrmann, Christin and Keat, K. and Assenmacher, C. and Tanes, Ceylan and Wilson, Naomi G. and Lordan, R. and Mrcela, Antonijo and Rauova, L. and Sengupta, Arjun and Das, U. S. and Joshi, Robin and Friedman, E. and Ritchie, M. and Bittinger, K. and Weljie, A. and Cadwell, Ken and Bushman, Frederic D. and Wu, Gary D. and Fitzgerald, G. and Ricciotti, E.}
}

Abstract

NSAIDs are the most widely used medications for the management of chronic pain; however, they are associated with numerous gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy is thought to be primarily due to inhibition of both COX-1 and -2, which results in suppression of prostaglandin synthesis. Yet surprisingly, we found that concomitant postnatal deletion of Cox-1 and -2 over 10 months failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor. Cox double-knockout mice exhibited a distinct gut microbiome composition, and cohousing them with controls rescued their dysbiosis and delayed the onset of NSAID-induced GI bleeding. In both the UK Biobank and All of Us human cohorts, coadministration of antibiotics with NSAIDs was associated with an increased frequency of GI bleeding. These results showed that prostaglandin suppression played a trivial role in NSAID-induced enteropathy. However, Cox deletion caused dysbiosis of the gut microbiome, which amplified the enteropathic response to NSAIDs.